MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma

Launched by OHSU KNIGHT CANCER INSTITUTE · Oct 8, 2018

Keywords

ClinConnect Summary

This clinical trial, called MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma, is examining how well three different portable imaging systems can help find melanoma, a type of skin cancer, compared to a visit to a dermatologist. Researchers want to see if these imaging methods can effectively identify skin issues early on, which is important for successful treatment before the cancer spreads.

If you're between the ages of 18 and 80 and have participated in certain free skin cancer screenings at Oregon Health & Science University (OHSU) in 2021 or 2022, you might be eligible for this trial. This includes those who have been told by a healthcare provider that they have a pigmented skin lesion needing a biopsy, as well as those with benign or unusual moles who are interested in the imaging aspect of the study. Participants will have the opportunity to have their skin examined using these advanced imaging techniques, which might help in understanding how effective they are for early detection of skin cancer. It's important to note that anyone with an allergy to the anesthetic lidocaine cannot join the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Persons who participate in the free skin cancer screening at the PDX Skincare Festival at Oregon Health \& Science University (OHSU) in 2021/2022 (date pending) and are informed by a provider that they have a pigmented lesion for which a biopsy is recommended are potentially eligible to participate in this study.
• • Persons who participate in the free skin cancer screening at the War on Skin Cancer event at OHSU in 2021/2022 (date pending) or other dates and locations and are informed by a provider that they have a clinically benign or atypical nevi are eligible to participate in the imaging portion of this study. No biopsy will be offered to these participants.
• • Persons age 18-80 are eligible for the study
• • Persons of any sex can be enrolled.
• • Persons of any race are eligible but we anticipate that most participants will be Non-Hispanic whites due to the prevalence of melanoma and other skin cancers in this group.
• • Only persons who can provide signed statement of informed consent will be enrolled.
• • Persons who are identified in OHSU Dermatology clinics or through OHSU e-visit and e-consult platforms as having a skin lesion in need of a biopsy for skin cancer
• • Persons identified via the Melanoma Community Registry (MCR) (IRB approved: 00010561)
• Exclusion Criteria:
• • Allergy to the anesthetic (lidocaine).